Vaxcell Bio Therapeutics
KOSDAQ:323990
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AAK AB (publ)
OTC:ARHUF
|
SE |
Vaxcell Bio Therapeutics
Goodwill
Vaxcell Bio Therapeutics
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics
KOSDAQ:323990
|
Goodwill
₩2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Goodwill
₩11.9T
|
CAGR 3-Years
596%
|
CAGR 5-Years
185%
|
CAGR 10-Years
129%
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Goodwill
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Goodwill
₩2.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vaxcell Bio Therapeutics
Glance View
Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. The company is headquartered in Hwasun, Jeollanam-Do and currently employs 47 full-time employees. The company went IPO on 2020-09-22. The firm's pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The firm sells its products in domestic and overseas markets.
See Also
What is Vaxcell Bio Therapeutics's Goodwill?
Goodwill
2.4B
KRW
Based on the financial report for Dec 31, 2024, Vaxcell Bio Therapeutics's Goodwill amounts to 2.4B KRW.
